HealthTech ETFs: A Guide for Investors

July 10, 2024

In today's rapidly evolving financial landscape, HealthTech ETFs (Exchange-Traded Funds) have emerged as a compelling investment vehicle for those looking to capitalize on the intersection of healthcare and technology. HealthTech ETFs are designed to track the performance of companies involved in innovative healthcare technologies, ranging from digital health platforms and telemedicine services to biotechnology advancements and wearable health devices. These funds offer investors a diversified portfolio, reducing risk while providing exposure to cutting-edge sectors that are transforming the healthcare industry.

The importance of HealthTech cannot be overstated. As the world continues to grapple with global health challenges and an aging population, the demand for innovative healthcare solutions is on the rise. HealthTech companies are at the forefront of addressing these needs, developing technologies that enhance patient care, improve diagnostic accuracy, and streamline healthcare delivery. This growing reliance on technology in healthcare has made HealthTech a vital area for investors seeking growth opportunities in the modern market.

This blog aims to serve as a comprehensive guide for investors interested in HealthTech ETFs. We will explore the basics of HealthTech ETFs, the benefits and risks associated with investing in them, and provide insights into key considerations for building a robust HealthTech investment portfolio. Whether you are a seasoned investor or new to the world of ETFs, this guide will equip you with the knowledge needed to make informed investment decisions in the dynamic HealthTech sector.

Understanding HealthTech ETFs

Exchange-Traded Funds (ETFs) are investment funds traded on stock exchanges, much like individual stocks. They hold a diversified portfolio of assets, such as stocks, bonds, or commodities, and are designed to track the performance of a specific index or sector. ETFs offer several advantages, including liquidity, cost-efficiency, and the ability to invest in a broad market segment without the need to buy individual stocks.

ETFs are structured to provide investors with the best of both worlds: the diversification of mutual funds and the flexibility of stock trading. They can be bought and sold throughout the trading day at market prices, unlike mutual funds, which are priced only at the end of the trading day. This intraday trading capability makes ETFs a popular choice for investors seeking both diversification and flexibility.

Specific Focus on HealthTech ETFs: What They Include and Exclude

HealthTech ETFs are a subset of sector-specific ETFs that focus on companies operating at the intersection of healthcare and technology. These ETFs typically include:

Digital Health Platforms: Companies providing telemedicine, electronic health records (EHRs), and mobile health applications.

Biotechnology Firms: Companies involved in genetic engineering, molecular diagnostics, and drug development.

Medical Device Manufacturers: Firms producing innovative medical devices and equipment.

Health Informatics: Companies specializing in healthcare data analytics, health information systems, and AI-driven diagnostics.

Wearable Technology: Companies developing wearable devices that monitor health metrics such as heart rate, sleep patterns, and physical activity.

HealthTech ETFs generally exclude companies that are primarily involved in traditional pharmaceuticals, medical services without a technological component, and general healthcare providers. This focused approach allows investors to specifically target the technological advancements reshaping the healthcare landscape.

Differences Between HealthTech ETFs and Other Healthcare-Related ETFs

While HealthTech ETFs concentrate on the technological innovations within the healthcare sector, other healthcare-related ETFs might have a broader or different focus. Here are some key distinctions:

Biotechnology ETFs: These funds focus exclusively on biotech companies involved in drug discovery, genetic research, and molecular biology. While there is overlap with HealthTech ETFs, biotech ETFs do not typically include companies outside of drug development and genetic engineering.

Pharmaceutical ETFs: These ETFs invest in companies that manufacture and sell medications. They often focus on larger, established pharmaceutical companies and exclude smaller, innovative HealthTech firms.

Healthcare Sector ETFs: These funds provide exposure to the entire healthcare sector, including pharmaceuticals, healthcare providers, medical equipment manufacturers, and health insurers. They offer broad diversification but may not focus specifically on technological innovations.

Medical Device ETFs: These ETFs target companies that produce medical devices and equipment. While there is some overlap with HealthTech ETFs, they may not include firms focused on digital health or health informatics.

By understanding these distinctions, investors can make more informed decisions about where to allocate their resources based on their investment goals and risk tolerance. HealthTech ETFs offer a unique opportunity to invest in the future of healthcare technology, providing a focused approach to capturing growth in this dynamic sector.

Benefits of Investing in HealthTech ETFs

Diversification: Spreading Risk Across Multiple Companies

One of the primary benefits of investing in HealthTech ETFs is the diversification they offer. By investing in a single ETF, investors gain exposure to a wide range of companies within the HealthTech sector. This diversification spreads risk across multiple entities, reducing the impact of poor performance by any single company. For example, if a particular digital health platform faces setbacks, the ETF’s performance may still remain robust due to the strength of other holdings in areas like biotechnology or wearable technology. This risk mitigation is a key advantage, providing a buffer against volatility inherent in individual stocks.

Exposure to Innovation and Cutting-Edge Technologies

HealthTech ETFs provide investors with direct exposure to the forefront of healthcare innovation. The companies included in these ETFs are often leaders in developing and implementing new technologies that have the potential to revolutionize patient care and healthcare delivery. By investing in HealthTech ETFs, investors support and benefit from advancements in areas such as telemedicine, AI-driven diagnostics, and genomic research. This exposure not only aligns investors with future growth trends but also positions them to capitalize on breakthroughs that can lead to substantial market gains.

Potential for High Returns in a Growing Sector

The HealthTech sector is poised for significant growth, driven by increasing demand for advanced healthcare solutions and technological innovation. As healthcare systems worldwide strive to improve efficiency, reduce costs, and enhance patient outcomes, companies at the intersection of health and technology are seeing rapid adoption and expansion. HealthTech ETFs offer the potential for high returns by capturing this growth trajectory. The increasing integration of technology in healthcare, coupled with a strong emphasis on precision medicine, digital health, and personalized care, creates a fertile ground for investment opportunities. By investing in HealthTech ETFs, investors can tap into this growth potential and enjoy the financial rewards of being part of a burgeoning sector.

In summary, HealthTech ETFs offer a compelling investment opportunity through diversification, exposure to groundbreaking innovations, and the potential for high returns in a growing industry. As the healthcare landscape continues to evolve, these ETFs provide a strategic way for investors to participate in the future of healthcare technology.

Key HealthTech ETFs to Consider

Overview of Popular HealthTech ETFs

Investors interested in HealthTech ETFs have several compelling options to choose from. Here, we provide an overview of some of the most popular HealthTech ETFs:

ARK Genomic Revolution ETF (ARKG) The ARK Genomic Revolution ETF focuses on companies involved in the genomics and biotechnology sectors. This ETF invests in companies that are likely to benefit from advancements in gene editing, DNA sequencing, and personalized medicine.

Global X Telemedicine & Digital Health ETF (EDOC) The Global X Telemedicine & Digital Health ETF targets companies that are leading the way in telemedicine and digital health. This includes firms offering telehealth services, healthcare information systems, and remote patient monitoring solutions.

iShares U.S. Medical Devices ETF (IHI) The iShares U.S. Medical Devices ETF invests in companies that manufacture and distribute medical devices and equipment. This ETF provides exposure to the medical devices sector, which is a key component of HealthTech.

SPDR S&P Health Care Equipment ETF (XHE) The SPDR S&P Health Care Equipment ETF focuses on companies in the health care equipment and supplies industry. It includes firms that produce advanced medical technologies and devices.

Analysis of the Top Holdings Within These ETFs

ARK Genomic Revolution ETF (ARKG)

CRISPR Therapeutics (CRSP): A leader in gene editing technology, CRISPR Therapeutics is pioneering the development of CRISPR/Cas9-based therapeutics for serious diseases.

Teladoc Health (TDOC): A key player in the telemedicine space, Teladoc Health provides virtual healthcare services, allowing patients to consult with doctors remotely.

Editas Medicine (EDIT): Another prominent gene editing company, Editas Medicine focuses on developing transformative genomic medicines to treat a range of serious diseases.

Global X Telemedicine & Digital Health ETF (EDOC)

Teladoc Health (TDOC): As mentioned, Teladoc Health is a major component of this ETF, underscoring its importance in the digital health landscape.

Ping An Healthcare (1833.HK): This Chinese company offers a comprehensive range of online healthcare services, including consultations, health management, and wellness programs.

Veeva Systems (VEEV): Veeva Systems specializes in cloud-based software for the life sciences industry, providing solutions for regulatory compliance and clinical data management.

iShares U.S. Medical Devices ETF (IHI)

Abbott Laboratories (ABT): A global healthcare leader, Abbott Laboratories produces a wide range of medical devices, diagnostics, and nutritional products.

Medtronic (MDT): Medtronic is one of the largest medical device companies in the world, known for its innovative products in cardiovascular, diabetes, and neurology.

Thermo Fisher Scientific (TMO): This company provides essential tools and technologies for scientific research, including diagnostic tests and laboratory equipment.

SPDR S&P Health Care Equipment ETF (XHE)

Abbott Laboratories (ABT): As with the iShares ETF, Abbott Laboratories is a significant holding, highlighting its dominance in the medical devices field.

Boston Scientific (BSX): Boston Scientific develops a variety of medical solutions for interventional medical specialties, including cardiology and neurology.

Intuitive Surgical (ISRG): Known for its robotic-assisted surgical systems, Intuitive Surgical is revolutionizing minimally invasive surgery with its da Vinci systems.

In conclusion, investing in HealthTech ETFs offers a strategic way to gain exposure to the rapidly growing and innovative healthcare technology sector. By understanding the composition, performance, and key holdings of various HealthTech ETFs, investors can make informed decisions to align their portfolios with the future of healthcare.

Factors to Consider Before Investing

Market Trends and Future Outlook for HealthTech

The HealthTech sector is characterized by rapid innovation and significant growth potential. Key trends driving this market include the increasing adoption of digital health solutions, advancements in genomic medicine, the proliferation of wearable health devices, and the integration of artificial intelligence in healthcare.

Telemedicine and Digital Health: The COVID-19 pandemic accelerated the adoption of telemedicine and digital health platforms, making them essential components of modern healthcare. This trend is expected to continue as patients and providers recognize the convenience and efficiency of remote healthcare services.

Genomics and Personalized Medicine: Advances in genomic sequencing and personalized medicine are revolutionizing the treatment of diseases. These technologies enable more accurate diagnoses and tailored treatments, which can improve patient outcomes and reduce healthcare costs.

Wearable Health Devices: The market for wearable health devices, such as fitness trackers and smartwatches, is expanding rapidly. These devices provide real-time health data, empowering individuals to monitor and manage their health proactively.

Artificial Intelligence: AI is being increasingly integrated into healthcare for tasks such as predictive analytics, diagnostic imaging, and personalized treatment plans. The ability of AI to analyze vast amounts of data quickly and accurately is transforming healthcare delivery.

Investors should keep an eye on these trends and consider how they might influence the performance of HealthTech ETFs. Staying informed about the latest developments and future outlook of the HealthTech sector can help investors make strategic decisions.

ETF Expense Ratios and Fees

Expense ratios and fees are critical factors to consider when evaluating HealthTech ETFs. The expense ratio represents the annual cost of owning the ETF, expressed as a percentage of the investment. Lower expense ratios are generally more favorable, as they reduce the overall cost of the investment and can enhance returns over time.

For example, the iShares U.S. Medical Devices ETF (IHI) has a relatively low expense ratio of 0.43%, making it an attractive option for cost-conscious investors. In contrast, the ARK Genomic Revolution ETF (ARKG) has a higher expense ratio of 0.75%, which reflects the active management and specialized focus of the fund.

It's important to compare the expense ratios of different HealthTech ETFs and weigh them against other factors, such as the fund's performance, holdings, and investment strategy. While lower fees are preferable, they should not be the sole criterion for selecting an ETF.

The Importance of Understanding Underlying Assets and Their Performance

Investors should thoroughly understand the underlying assets of a HealthTech ETF and assess their performance. This involves examining the fund's holdings, the sectors and industries it covers, and the individual companies included in the portfolio.

Holdings Analysis: Reviewing the top holdings of an ETF provides insight into its investment focus and risk exposure. For example, an ETF heavily weighted towards biotechnology firms might be more volatile but offer higher growth potential compared to one focused on established medical device companies.

Sector and Industry Coverage: Different HealthTech ETFs may emphasize various sub-sectors, such as telemedicine, genomics, or medical devices. Understanding the specific areas covered by an ETF helps investors align their investments with their interests and risk tolerance.

Performance Evaluation: Analyzing the historical performance of an ETF and its underlying assets can provide valuable information about its potential future returns. Look at the fund's performance over different time periods, compare it with benchmarks, and consider how it has performed in various market conditions.

In conclusion, investing in HealthTech ETFs requires careful consideration of market trends, expense ratios, and the performance of underlying assets. By evaluating these factors, investors can make informed decisions and position themselves to benefit from the growth and innovation in the HealthTech sector.

How to Invest in HealthTech ETFs

Steps to Start Investing: Opening a Brokerage Account, Choosing the Right Platform

Opening a Brokerage Account To start investing in HealthTech ETFs, the first step is to open a brokerage account. Here’s how to get started:

Research Brokerage Firms: Look for a reputable brokerage firm that offers a wide range of ETF options, competitive fees, and robust customer service. Popular online brokers include Charles Schwab, Fidelity, and Robinhood.

Create an Account: Visit the brokerage firm’s website and follow the steps to create an account. You will need to provide personal information, such as your name, address, and Social Security number.

Fund Your Account: Once your account is set up, you’ll need to deposit funds. This can be done via bank transfer, check, or other methods offered by the brokerage.

Choosing the Right Platform Selecting the right investment platform is crucial for managing your investments efficiently. Consider the following factors:

User Interface: Choose a platform with an intuitive and user-friendly interface, especially if you are a beginner.

Research Tools: Ensure the platform provides robust research tools, including market analysis, news updates, and performance tracking.

Fees and Commissions: Compare fees and commissions across different platforms. Some brokers offer commission-free trading on ETFs.

Customer Support: Opt for a platform with reliable customer support to assist with any issues or questions.

Tips for Beginners: Setting Investment Goals, Understanding Risk Tolerance

Setting Investment Goals Before investing, it’s important to define your investment goals. Ask yourself the following questions:

What are your financial objectives? Are you saving for retirement, a major purchase, or simply looking to grow your wealth?

What is your investment timeline? Are you planning to invest for the short term or long term? Longer investment horizons typically allow for more aggressive strategies.

How much can you invest? Determine how much money you can allocate to HealthTech ETFs without compromising your financial stability.

Understanding Risk Tolerance Your risk tolerance is the degree of variability in investment returns you are willing to withstand. Consider the following:

Risk Assessment: Assess your comfort level with market fluctuations. Are you willing to take on higher risk for potentially higher returns, or do you prefer a more conservative approach?

Diversification: Diversifying your portfolio can help manage risk. HealthTech ETFs themselves offer diversification within the HealthTech sector, but consider balancing your overall portfolio with investments in other sectors.

Long-Term vs. Short-Term Investment Strategies

Long-Term Investment Strategies Long-term investing involves holding investments for several years, allowing them to grow over time. Benefits include:

Compounding Returns: The power of compounding can significantly increase your investment value over the long term.

Reduced Impact of Volatility: Long-term investments can weather market fluctuations and economic cycles better than short-term investments.

Lower Taxes: Long-term capital gains are usually taxed at a lower rate than short-term gains.

When employing a long-term strategy for HealthTech ETFs:

Focus on Growth Potential: Invest in ETFs with strong growth potential in the HealthTech sector.

Regular Contributions: Consider making regular contributions to your investment, such as monthly or quarterly, to take advantage of dollar-cost averaging.

Short-Term Investment Strategies Short-term investing involves buying and selling investments within a shorter timeframe, ranging from a few months to a couple of years. Considerations include:

Higher Volatility: Short-term investments can be more volatile and require active management.

Market Timing: Success in short-term investing often depends on accurately timing the market, which can be challenging.

Higher Taxes: Short-term capital gains are taxed at a higher rate than long-term gains.

When employing a short-term strategy for HealthTech ETFs:

Stay Informed: Keep up with market trends and news that can impact the HealthTech sector.

Set Clear Exit Points: Determine your target profit levels and stop-loss limits to manage risk effectively.

Be Prepared to Act: Short-term investing may require quick decision-making to capitalize on market opportunities.

In conclusion, investing in HealthTech ETFs involves understanding market trends, evaluating expense ratios, and analyzing underlying assets. By setting clear investment goals, understanding your risk tolerance, and choosing the appropriate investment strategy, you can navigate the dynamic HealthTech sector and potentially achieve your financial objectives. Whether you are a long-term investor seeking growth or a short-term trader looking for quick gains, HealthTech ETFs offer a versatile and promising investment avenue.

Risks and Challenges

Volatility and Market Fluctuations

HealthTech ETFs, like all investments, are subject to market volatility and fluctuations. The HealthTech sector, in particular, can be highly volatile due to its reliance on innovation and emerging technologies. Factors that contribute to this volatility include:

Innovation Risks: HealthTech companies often invest heavily in research and development. While this can lead to significant breakthroughs, it can also result in failures or delays that negatively impact stock prices.

Market Sentiment: The HealthTech sector can be sensitive to changes in market sentiment. News about regulatory approvals, technological advancements, or high-profile failures can lead to swift price movements.

Economic Conditions: Broader economic conditions, such as interest rates, inflation, and economic growth, can also affect the performance of HealthTech ETFs. During economic downturns, investors may become risk-averse, leading to reduced investment in high-growth sectors like HealthTech.

Regulatory and Ethical Considerations in HealthTech

The HealthTech sector is subject to stringent regulatory oversight and ethical considerations, which can pose risks and challenges for investors:

Regulatory Approvals: Many HealthTech companies need to obtain regulatory approvals for their products and technologies. The approval process can be lengthy, uncertain, and costly. Delays or rejections can significantly impact the financial performance of these companies.

Compliance Costs: Ensuring compliance with regulatory standards can be expensive. HealthTech companies must invest in quality control, clinical trials, and regulatory documentation, which can strain their financial resources.

Ethical Concerns: Ethical considerations, such as data privacy, patient consent, and the ethical use of AI, are crucial in the HealthTech sector. Public scrutiny and regulatory actions related to these issues can affect the reputation and profitability of HealthTech companies.

The Impact of Technological Advancements and Competition

Technological advancements and competition are inherent aspects of the HealthTech sector, presenting both opportunities and challenges:

Rapid Technological Change: The fast pace of technological advancements can make it challenging for companies to stay ahead. While innovation drives growth, it also requires continuous investment in R&D. Companies that fail to innovate may lose their competitive edge.

Competitive Landscape: The HealthTech sector is highly competitive, with numerous companies vying for market share. Intense competition can lead to price wars, reduced profit margins, and increased pressure to continuously innovate.

Disruption Risks: New technologies can disrupt existing business models. For example, advancements in telemedicine and AI-driven diagnostics may render traditional healthcare delivery methods obsolete. Investors need to monitor technological trends to identify potential disruptors and assess their impact on existing investments.

Notable Labs, a clinical-stage precision oncology company, utilizes its Predictive Precision Medicines Platform (PPMP) to bio-simulate cancer treatments and predict patient responses, enhancing therapeutic precision. This innovative approach positions Notable Labs as a key player in the HealthTech sector, making it an attractive component of HealthTech ETFs for investors seeking exposure to advancements in precision medicine and oncology

Recap of the potential benefits and risks

Investing in HealthTech ETFs presents a unique opportunity to tap into the rapidly evolving intersection of healthcare and technology. Here are the key benefits and risks to consider:

Potential Benefits:

Diversification: HealthTech ETFs offer exposure to a broad range of companies within the sector, spreading risk across multiple entities.

Exposure to Innovation: These ETFs include companies at the forefront of healthcare innovation, providing access to cutting-edge technologies and potential growth.

High Returns: The HealthTech sector’s growth potential can lead to substantial returns, particularly as demand for advanced healthcare solutions continues to rise.

Potential Risks:

Volatility: The HealthTech sector can be highly volatile, with stock prices influenced by innovation cycles, market sentiment, and economic conditions.

Regulatory Hurdles: Companies in the HealthTech sector face stringent regulatory requirements, and delays or failures in obtaining approvals can impact financial performance.

Technological Competition: Rapid technological advancements and intense competition can challenge companies to continually innovate and maintain their market position.

While HealthTech ETFs offer promising investment opportunities, it is crucial for investors to conduct thorough research and due diligence before making any investment decisions. Consider the following steps:

Understand the Sector: Stay informed about the latest trends, technological advancements, and regulatory changes in the HealthTech sector.

Analyze ETFs: Compare different HealthTech ETFs based on their holdings, performance, expense ratios, and investment strategies.

Assess Risk Tolerance: Evaluate your risk tolerance and investment goals to ensure that investing in HealthTech ETFs aligns with your overall financial plan.

Monitor Investments: Continuously monitor your investments and stay updated on industry developments that could impact the performance of your ETFs.

The future of HealthTech ETFs looks bright as the integration of technology in healthcare continues to accelerate. As we move forward, the demand for innovative healthcare solutions, driven by an aging population and global health challenges, is expected to grow. HealthTech companies are well-positioned to address these needs through advancements in telemedicine, genomics, AI, and wearable health devices.

HealthTech ETFs can play a valuable role in a diversified investment portfolio. They provide exposure to a high-growth sector while offering the benefits of diversification and professional management. For investors seeking to capitalize on the transformative potential of healthcare technology, HealthTech ETFs represent a strategic and promising investment avenue.

In summary, HealthTech ETFs offer a blend of growth potential and diversification, making them an attractive option for forward-thinking investors. By understanding the benefits, risks, and industry dynamics, and by conducting thorough research, investors can make informed decisions and position themselves to benefit from the future of healthcare technology.

< Older Post Newer Post >

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024

Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.

A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024

Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.

A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024

Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.

A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024

Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.

A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024

Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.

A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024

Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.

Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024

Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.

A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024

Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.

A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024

Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.

A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024

Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial. Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.